CCX 140

Drug Profile

CCX 140

Alternative Names: CCX-140B; CCX140

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Vifor
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Focal segmental glomerulosclerosis
  • Research Kidney disorders
  • No development reported Type 2 diabetes mellitus
  • Discontinued Multiple sclerosis; Vascular restenosis

Most Recent Events

  • 09 Mar 2018 Phase-II clinical trials in Focal segmental glomerulosclerosis in USA (PO) before March 2018
  • 07 Nov 2017 ChemoCentryx plans a registration-supporting trial for Focal segmental glomerulosclerosis in Q4 2017
  • 31 Mar 2017 ChemoCentryx has patent protection for CCX 140 in USA, Europe, Japan, Australia, Canada, China, Israel, Mexico and Hong Kong
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top